Serrapeptase vs Vesugen
A side-by-side research comparison of Serrapeptase and Vesugen across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Serrapeptase | Vesugen |
|---|---|---|
| Full name | Serrapeptase (Serratiopeptidase) | Vesugen (Lys-Glu-Asp Vascular Bioregulator) |
| Category | Cardiovascular | Cardiovascular |
| Status | Dietary supplement | Research compound (peptide bioregulator) |
| Mechanism | Degrades non-living tissue including fibrin, blood clots, mucus, and arterial plaque without harming living cells. Inhibits bradykinin release and reduces prostaglandin synthesis for anti-inflammatory effects. | As a signal peptide (Lys-Glu-Asp), it is proposed to enter cells and regulate gene expression in vascular tissue, supporting endothelial function, vascular tone, and normal vessel-wall maintenance. |
| Molecular weight | ~52,000 Da | ~390 Da |
| Half-life | ~4-6 hours | Short (peptide) |
| Bioavailability | Oral (enteric-coated required); detectable in bloodstream | Oral (encapsulated) or subcutaneous |
| Typical dose | 120,000-240,000 SPU | ~1-2 capsules/day or short injectable courses |
| Frequency | Daily on empty stomach | Once daily |
| Route | Oral (enteric-coated) | Oral capsule or subcutaneous |
Serrapeptase reported benefits
- Reduced inflammation and swelling
- Arterial plaque modulation
- Mucus/biofilm breakdown
- Post-surgical recovery
- Sinus/respiratory clearing
- Pain reduction
Vesugen reported benefits
- Vascular/endothelial support
- Proposed vascular tissue regulation
- Short course-based protocol
- Part of bioregulator longevity systems
Related comparisons
Research and educational reference only. Not medical advice.